Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4004306 | American Journal of Ophthalmology | 2008 | 9 Pages |
Abstract
The fluoroquinolones were consistently active in MSSA, S. pneumoniae, and H. influenzae. After more than a decade of intensive ciprofloxacin and levofloxacin use as systemic therapy, 100% of ocular S. pneumoniae isolates were susceptible to gatifloxacin, levofloxacin, and moxifloxacin; nonsusceptibility to ciprofloxacin was less than 15%. High-level in vitro MRSA resistance suggests the need to consider alternative therapy to fluoroquinolones when MRSA is a likely pathogen.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Penny A. Asbell, Kathryn A. Colby, Sophie Deng, Peter McDonnell, David M. Meisler, Michael B. Raizman, John D. Jr, Daniel F. Sahm,